Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Inclusion Criteria: * Patients with stage IIIA, or stage IIIC with positive cytologic washings/ascites, adnexal spread, or serosal involvement, or stage IV (by virtue of intraperitoneal disease spread) histologically confirmed endometrial cancer (endometrioid, serous, clear cell, squamous/adenosquamous, undifferentiated, or mixed histologies) * Patients must be optimally cytoreduced with less than or equal to 2 cm residual disease * Absolute neutrophil count (ANC) greater than or equal to 1,500/mm\^3, equivalent to Common Toxicity Criteria (Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0 \[v3.0\]) grade 1 * Platelets greater than or equal to 100,000/mm\^3 (CTCAE v3.0 grade 0-1) * Hemoglobin greater than or equal to 10 g/dl (CTCAE v3.0 grade 1) * Creatinine less than or equal to 2 mg/% or 24 hour creatinine clearance \> 50 ml/min * Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE v3.0 grade 1) * Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1) * Neuropathy (sensory and motor) less than or equal to CTCAE v3.0 grade 1 * Patients must have normal ejection fraction * Patients must be enrolled within 8 weeks of surgery * Patients who have met the pre-entry requirements * Patients must have signed an approved informed consent and authorization permitting release of personal health information * Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2 Exclus…